HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mandy Jackson

Mandy Jackson is the US West Coast Editor for Scrip Intelligence. Mandy reports on daily biopharma news and regularly interviews everyone from big pharma CEOs to biotech startup founders about the business strategy behind their finance, dealmaking and drug development news. She also has an interest in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, and business development trends. Mandy has been a business news reporter for more than 15 years, covering biotech and pharma companies, biotech law and commercial real estate. She is based in San Diego, California – the venue for many medical and biopharma industry meetings.
Set Alert for Articles By Mandy Jackson

Latest From Mandy Jackson

Finance Watch: Biopharma Stocks See Big Post-IPO Jumps

Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.

Financing Business Strategies

Troriluzole Fails First Phase III Test As Biohaven Looks Beyond Migraine

Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.

Clinical Trials Neurology

Zogenix’s Fintepla Reduces Drop Seizure Rates, But Is It Enough?

Despite positive Phase III results in Lennox-Gastaut syndrome, the effect of the company’s low-dose fenfluramine on serious seizures may not be as good as seen with GW Pharma’s Epidiolex. 

Clinical Trials Comparative Effectiveness

BMS/Celgene Post-Merger Early R&D Strategy: Partnerships Are Still Key, Vessey Says

Research and early development head Rupert Vessey, who had a similar role at Celgene, told Scrip that integration of the company’s pipeline into Bristol is nearly complete with few overlapping programs.

Research and Development Strategies Deals

BMS Earnings Beat Estimates, But Opdivo Sales Slide Continues

The company believes the PD-1 inhibitor’s recent declines will be reversed through new indications, providing revenue growth along with other new products by the time Revlimid faces generics in 2022.

Sales & Earnings ImmunoOncology

Merck: It’s Not Just Keytruda Driving Future Growth

The company will depend on Keytruda for growth after spinning out some franchises, but executives argued during its Q4 earnings call that there will be much more to Merck than the cancer blockbuster.

Business Strategies Sales & Earnings
See All
UsernamePublicRestriction

Register